Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis (NAPPREMS)

NCT03046251 Phase 4 COMPLETED Results posted

The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.

Details

Lead sponsor	State University of New York at Buffalo
Phase	Phase 4
Status	COMPLETED
Enrolment	30
Start date	2015-08
Completion	2023-12

Conditions

• Multiple Sclerosis

Interventions

• Natalizumab

Primary outcomes

• Relapses Post Partum — 52 weeks
  The primary endpoint are the relapses during 1 year post-delivery in patients treated with natalizumab. This will be compared to the relapse frequency in the parallel control group.

Countries

United States